Inovio Pharmaceuticals Inc (INO)

[Ubertino]

Take note of these subtleties
While it's great to see Inovio delivering a rare (but expected) profit, investors would be wise to focus on the subtleties of Inovio's report, which are much more important.

For instance, Inovio's collaboration with AstraZeneca during the third quarter marked the second big-name pharma company that it's snagged a development deal with. If you recall, Inovio and Roche currently have a licensing deal in place for the development of INO-1800, the company's hepatitis B candidate. Having two brand-name pharmaceutical partners implies that Inovio may have the ability to monetize its pipeline and/or development platform on an as-needed basis. This bodes very well for the company's long-term future and its ability to avoid cash burn concerns. The $700 million in development, regulatory, and sales milestones that Inovio can earn for the advancement of INO-3112 doesn't hurt, either.

http://www.fool.com/investing/general/2015/11/12/inovio-pharmaceuticals-produces-a-rare-quarterly-p.aspx?source=eptadnlnk0000002&utm_source=advfn&utm_medium=cpc&utm_campaign=investorshub

Noted!

Looking for big things ahead!!